Incannex Healthcare Reports Key Development in Drug Program for Smoking Cessation

FDA Provides Guidance on Incannex's CannQuit-N Clinical Trials during Pre-IND Meeting

Incannex Healthcare Inc., a leading biotech company specializing in cannabinoid and psychedelic medicine, has made a significant breakthrough in its drug program for smoking cessation. The company recently had a productive pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding its investigational chewing gum, CannQuit-N.